Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Genitourinary tumours, prostate

1734 - Lutetium-177 PSMA (LuPSMA) Theranostics Phase II trial: Efficacy, safety and QoL in patients with castrate-resistant prostate cancer treated with LuPSMA


08 Sep 2017


Genitourinary tumours, prostate


Michael Hofman


Annals of Oncology (2017) 28 (suppl_5): v269-v294. 10.1093/annonc/mdx370


M.S. Hofman1, S. Sandhu1, P. Eu1, J. Price2, T. Akhurst2, A. Iravani2, G. Kong2, A. Ravi-Kumar2, S. Williams1, S. Thang2, D. Murphy1, M. Scalzo2, R.J. Hicks2, J. Violet2

Author affiliations

  • 1 Sir Peter Maccallum Department Of Oncology, University Of Melbourne, Peter MacCallum Cancer Centre, 3000 - Melbourne/AU
  • 2 Centre For Molecular Imaging, Peter MacCallum Cancer Centre, 3000 - Melbourne/AU


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1734


Progressive metastatic castrate-resistant prostate carcinoma (mCRPC) is a highly lethal condition. Lutetium-177 (177Lu)-PSMA617, a radiolabelled small molecule, binds with high affinity to prostate specific membrane antigen (PSMA) enabling beta particle therapy targeted to mCRPC.


In this phase II prospective trial, 30 pts with PSMA-avid mCRPC who had failed standard therapies received up to 4 cycles of 177Lu-PSMA617 every 6 weeks. The primary endpoints were PSA and imaging response (PCWG2) and toxicity (CTCAE v4). Other endpoints were quality of life (EORTC QLQ-C30/BM22, BPI), dosimetry, PFS and OS.


All patients were enrolled between 10/2015 and 12/2016 (median age 69 yr, ECOG 1; PSA doubling time 2.2 months) with 3 pts awaiting a final treatment cycle. 87% received prior chemotherapy, 47% cabazitaxel and 83% prior abiraterone and/or enzalutamide. Mean dose was 7.5 GBq (range 4.4 – 8.7 GBq) prospectively adjusted according tumour burden, renal function and weight. At this interim analysis, 17/30 pt (57%) achieved PSA decline >50%, including 11/30 (37%) with decline >80%. In 17 pt with soft tissue disease, objective response (RECIST PR+CR) occurred in 12 pt (71%). Most common adverse events were grade 1 xerostomia (19 pt, 63%) and nausea (15 pt, 50%). Grade 3 or higher hematoxicity occurred in 5 pt (17%); all had baseline thrombocytopenia and were reversible. Following the first cycle of LuPSMA, global health score improved significantly (≥10 points) in 11/30 pt (37%), while in those with bone pain, mean severity score improved significantly (≥ 10 points) in 9/21 pt (43%).


The LuPSMA Phase II trial provides evidence of high response rates and low toxicity with improved QoL and pain reduction in men with mCRPC who have failed conventional therapies.

Clinical trial identification

Australian New Zealand Clinical Trials Registry: ACTRN12615000912583. Universal Trial Number (UTN): U1111-1172-4095.

Legal entity responsible for the study

Peter MacCallum Cancer Centre, Melbourne, Australia


Investigator-initiated trial. Lutetium-177 (no carrier added) supplied by Australian National Nuclear Research and Development Organisation (ANSTO). PSMA617 supplied by Advanced Biochemical Compounds (ABX).


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.